產(chǎn)品詳情
簡單介紹：
Anti-PROCA1抗體產(chǎn)品質(zhì)量穩(wěn)定，實驗效果明顯，貨期快，價格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-PROCA1抗體用于**組化實驗,WB實驗,相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-PROCA1
Cat. Number:
Anti-PROCA1抗體KL-9188R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
PROCA1 is a 364 amino acid protein that belongs to the PROCA1 family and exists as two alternatively spliced isoforms. Conserved in dog, cow, mouse and rat, PROCA1 participates in calcium ion binding and phospholipase A2Anti-PROCA1抗體 activity. The gene that encodes PROCA1 maps to human chromosome 17q11.2. Chromosome 17 makes up over 2.5% of the human genome, with approximately 81 million bases encoding over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. BRCA1 is recognized as a genetic determinant of early onset breast cancer. Chromosome 17 is also linked to neurofibromatosis, dysregulated Schwann cell growth, Alexander disease, Birt-Hogg-Dube syndrome and Canavan disease。
Also known as:
PRCA1_HUMAN; Proca1; proline-rich cyclin Anti-PROCA1抗體A1-interacting protein; Protein interacting with cyclin A1; Protein PROCA1; RP23-185A18.6.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Sheep, .
●
Immunogen: KLH conjugated synthetic Anti-PROCA1抗體peptide derived from human PROCA1.
●
Predicted Molecular Weight: 41kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:50-200
Not yet tested in other applications. Anti-PROCA1抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-PROCA1抗體
Optimal working dilutions must be determined by the end user.
